A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2008

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 09 Dec 2008 Preliminary results announced by Aren Pharmaceuticals, indicating that the trial's primary and secondary endpoints have not been met. A full analysis is yet to be completed.
    • 01 May 2008 Integrated NCT00664664
    • 01 May 2008 The expected completion date for this trial is now 1 Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top